Evaluating response criteria in myelodysplastic/myeloproliferative neoplasms: a systematic review and meta-analysis.
International experts clarified response definitions for rare blood cancers, enabling clearer clinical trial comparisons and better treatment decisions.
This landmark international systematic review—authored by 19 experts from the MDS/MPN International Working Group across Europe, North America, and Australia—critically evaluated the performance and consistency of currently used response criteria in myelodysplastic/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. The work provides the evidence base for harmonizing response definitions, which is prerequisite for interpretable clinical trial endpoints in these genetically and clinically heterogeneous malignancies.
What the study was
- Study design
- systematic review + meta-analysis
- Category
- Other
- Maturity
- Validated
- Journal
- Blood Neoplasia
Why it surfaced
International consensus systematic review directly addressing the critical unmet need for standardized response criteria in MDS/MPN overlap—a rare hematologic malignancy cluster with high trial design complexity; high relevance to T1 watchlist and clinical practice.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.